Table of Content - Middle East And Turkey Chronic Liver Disease (CLD) Therapeutics Market

Chronic liver disease is associated with the progressive destruction of liver parenchyma for longer period of time (6 months) leading to liver fibrosis and cirrhosis. The main etiology of CLD include alcohol induced liver, hepatitis virus (B, C, and D), hepatocellular carcinoma (HCC), liver cancer, and fatty liver diseases. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others. Market players such as IceCure Medical, BioLineRx Ltd., Oramed Pharmaceuticals Inc., and BioLineRx Ltd. are engaged in the development of novel treatment options for CLD.

Middle East and Turkey chronic liver disease therapeutics market is estimated to be valued at USD 31.6 Bn in 2026 and is expected to reach USD USD 46.7 Bn by 2033, exhibiting a CAGR of 5.8% during the forecast period (2026-2033).

Market Dynamics

The increasing incidence of liver disease, growing geriatric population, Government and non-government awareness programs related to liver disease, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Turkey chronic liver disease therapeutics market over the forecast period.

According to National Library of Medicine, in the Middle East, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, with associated risk factors including Obesity, and type 2 Diabetes. The patient’s progress to develop Nonalcoholic Steatohepatitis (NASH) is about 20% to 30%. Younossi, a nationally recognized leader specializing in hepatology and gastroenterology, reported that in Middle East the prevalence to be highest (33%) in a meta-analysis on Global Epidemiology of NAFLD. Awareness with suspected NAFLD has increased over last two decades, but 95% of the patients are still unaware about having liver disease.

Key features of the study

This report provides an in-depth analysis of the Middle East and Turkey chronic liver Disease (CLD) therapeutics market, provides market size (USD Bn), and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Middle East and Turkey chronic liver disease (CLD) therapeutics market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
Middle East and Turkey chronic liver disease (CLD) therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey chronic liver disease (CLD) therapeutics market

Market Segmentation

By Disease Type
- Hepatitis
- Alcohol Induced Liver Disease
- Liver Cancer
- Fatty Liver Disease
- Others
By Drug Class
- Chemotherapy Drugs
- Targeted therapy
- Vaccines
- Immunoglobulin
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country Insights
- Turkey
- Saudi Arabia
- Israel
- UAE
- Egypt
- Rest of Middle East and Turkey
Key Players Insights
- Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum AB
- GlaxoSmithKline Plc
- Sanofi S.A
- Merck & Co., Inc.
- AbbVie Inc.
- Abbott Laboratories
- AstraZeneca plc
- Pfizer Inc.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Disease Type
  - Market Snippet, By Drug Class
  - Market Snippet, By Route of Administration
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Country
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
  - Impact Analysis
- Technological Evolution
- Regulatory Scenario
- Key Developments
- Collaboration and Acquisition
- Diagnosis Rate/Ratio
- Pipeline Analysis
- PEST Analysis
- Reimbursement Scenario
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Disease Type, 2026-2033 (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Hepatitis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Alcohol Induced Liver Disease
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Liver Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Fatty Liver Disease
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Drug Class, 2026-2033 (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Chemotherapy Drugs
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted therapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Vaccines
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunoglobulin
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Route of Administration, 2026–2033 (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Parenteral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Distribution Channel, 2026–2033 (USD Bn)
- Introduction
  - Market Share Analysis, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, 2021-2033
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Country, 2026–2033 (USD Bn)
- Introduction
  - Market Share Analysis, By Country, 2025, 2028, and 2033 (%)
  - Y-o-Y Growth Analysis, For Countries, 2021-2033
  - Middle East
    - Market Size and Forecast, By Country, 2021-2033 (USD Bn)
  - Turkey
    - Introduction
    - Market Size and Forecast, By Disease Type, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Drug Class, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Route of Administration, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
  - Saudi Arabia
    - Introduction
    - Market Size and Forecast, By Disease Type, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Drug Class, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Route of Administration, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
  - Israel
    - Introduction
    - Market Size and Forecast, By Disease Type, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Drug Class, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Route of Administration, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
  - UAE
    - Introduction
    - Market Size and Forecast, By Disease Type, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Drug Class, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Route of Administration, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
  - Egypt
    - Introduction
    - Market Size and Forecast, By Disease Type, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Drug Class, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Route of Administration, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
  - Rest of Middle East and Turkey
    - Introduction
    - Market Size and Forecast, By Disease Type, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Drug Class, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Route of Administration, 2021-2033 (USD Bn)
    - Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
Competitive Landscape
- Company Profiles
  - Hoffmann-La Roche AG
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Gilead Sciences, Inc.
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Intercept Pharmaceuticals, Inc.
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Swedish Orphan Biovitrum AB
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - GlaxoSmithKline Plc
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Sanofi S.A
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Merck & Co., Inc.
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - AbbVie Inc.
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Abbott Laboratories
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - AstraZeneca plc.
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
  - Pfizer Inc.
    - Company Overview
    - Product Portfolio
    - Key Developments
    - Financial Performance
    - Strategies
Section
- References
- Research Methodology
- About us and Sales Contact

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE